Shots:
- Samsung Bioepis and Phrontline Biopharma have entered a global agreement to develop, manufacture, and commercialize two ADC assets, including TJ108
- Under the deal, Phrontline will receive an upfront payment and potential milestone payments. Phrontline will develop bispecific, dual-payload ADCs using its proprietary platforms. As part of the agreement, Samsung Bioepis received exclusive rights to develop and commercialize a TOP1 inhibitor payload for ADCs
- TJ108 is an ADC targeting EGFR and HER3, combining TOP1 and tubulin inhibitors to treat cancers with overexpressed receptors linked to aggressive growth and metastasis
Ref: Samsung Bioepis | Image: Samsung Bioepis and Phrontline | Press Release
Related News:- Samsung Bioepis Collaborates with Harrow to Commercialize its Ophthalmology Biosimilars in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
